Correction of the coagulation defect in hemophilia using a factor Xa variant with novel engineered protease function

Effective therapies are needed to control excessive bleeding in a range of clinical conditions. We describe a surprisingly useful approach to improve hemostasis in vivo using a variant of coagulation factor Xa (FXa(I16L)). This conformationally pliant derivative is partially inactive due to a defect...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanciu, Lacramioara, Toso, Raffaella, Margaritis, Paris, Pavani, Giulia, Kim, Haein, Schlachterman, Alexander, Liu, Jian-Hua, Clerin, Valerie, Pittman, Debra D., Rose-Miranda, Rosalind, Shields, Kathleen M., Erbe, David V., Tobin, James F., Arruda, Valder R., Camire, Rodney M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157830/
https://www.ncbi.nlm.nih.gov/pubmed/22020385
http://dx.doi.org/10.1038/nbt.1995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157830/
https://www.ncbi.nlm.nih.gov/pubmed/22020385
http://dx.doi.org/10.1038/nbt.1995

Ejemplares similares